Omar Abdel-Rahman1. 1. Clinical Oncology department, Faculty of medicine, Ain Shams University, Cairo, Egypt. omar.abdelrhman@med.asu.edu.eg.
Abstract
INTRODUCTION: This study assessed the prognostic impact of postoperative radiotherapy in patients with surgically resected malignant pleural mesothelioma (MPM). METHODS: MPM patients diagnosed between 2000 and 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. A propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TNM stage, and type of surgery). RESULTS: A total of 2166 patients were identified. The median age was 60 years (range 25-85 years), and 469 patients received postoperative radiotherapy. Both before and after propensity score matching, overall survival (P < 0.0001 and P = 0.012, respectively) was better in the postoperative radiotherapy group. When the overall survival was stratified by histology, postoperative radiotherapy did not improve the survival in sarcomatoid histology patients both before and after matching (P = 0.424 and P = 0.281, respectively). In multivariate analysis of the matched population, not receiving postoperative radiotherapy did not correlate with worse survival (hazard ratio: 1.175; P = 0.12). Factors associated with worse survival include sarcomatoid histology, nodal positivity, and age ≥70. CONCLUSION: Evidence from this analysis is insufficient on its own to routinely recommend postoperative radiotherapy for surgically resected MPM. However, large-scale prospective clinical trials are warranted to further evaluate this intervention in nonsarcomatoid histology.
INTRODUCTION: This study assessed the prognostic impact of postoperative radiotherapy in patients with surgically resected malignant pleural mesothelioma (MPM). METHODS: MPM patients diagnosed between 2000 and 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. A propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TNM stage, and type of surgery). RESULTS: A total of 2166 patients were identified. The median age was 60 years (range 25-85 years), and 469 patients received postoperative radiotherapy. Both before and after propensity score matching, overall survival (P < 0.0001 and P = 0.012, respectively) was better in the postoperative radiotherapy group. When the overall survival was stratified by histology, postoperative radiotherapy did not improve the survival in sarcomatoid histology patients both before and after matching (P = 0.424 and P = 0.281, respectively). In multivariate analysis of the matched population, not receiving postoperative radiotherapy did not correlate with worse survival (hazard ratio: 1.175; P = 0.12). Factors associated with worse survival include sarcomatoid histology, nodal positivity, and age ≥70. CONCLUSION: Evidence from this analysis is insufficient on its own to routinely recommend postoperative radiotherapy for surgically resected MPM. However, large-scale prospective clinical trials are warranted to further evaluate this intervention in nonsarcomatoid histology.
Entities:
Keywords:
Pleural mesothelioma; Postoperative radiotherapy; Prognosis; Radiotherapy; Surgery
Authors: Raja M Flores; Elyn Riedel; Jessica Scott Donington; William Alago; Ugonna Ihekweazu; Lee Krug; Kenneth Rosenzweig; Prasad S Adusumilli; Michele Carbone; Harvey I Pass Journal: J Thorac Oncol Date: 2010-10 Impact factor: 15.609
Authors: Andreas Rimner; Charles B Simone; Marjorie G Zauderer; Keith A Cengel; Valerie W Rusch Journal: Lancet Oncol Date: 2016-02 Impact factor: 41.316
Authors: Carl Blomberg; Jonas Nilsson; Georg Holgersson; Per Edlund; Michael Bergqvist; Linda Adwall; Simon Ekman; Daniel Brattström; Stefan Bergström Journal: Anticancer Res Date: 2015-05 Impact factor: 2.480
Authors: A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Péchoux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder Journal: Eur Respir J Date: 2009-08-28 Impact factor: 16.671
Authors: Rolf A Stahel; Oliver Riesterer; Alexandros Xyrafas; Isabelle Opitz; Michael Beyeler; Adrian Ochsenbein; Martin Früh; Richard Cathomas; Kristiaan Nackaerts; Solange Peters; Christoph Mamot; Alfred Zippelius; Carlo Mordasini; Clemens B Caspar; Katrin Eckhardt; Ralph A Schmid; Daniel M Aebersold; Oliver Gautschi; Wolfgang Nagel; Michael Töpfer; Jerome Krayenbuehl; Karin Ribi; Ilja Ciernik; Walter Weder Journal: Lancet Oncol Date: 2015-11-02 Impact factor: 41.316
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316
Authors: Christian Thieke; Nils H Nicolay; Florian Sterzing; Hans Hoffmann; Falk Roeder; Seyer Safi; Juergen Debus; Peter E Huber Journal: Radiat Oncol Date: 2015-12-30 Impact factor: 3.481
Authors: Amelia O Clive; Hazel Taylor; Lee Dobson; Paula Wilson; Emma de Winton; Niki Panakis; Justin Pepperell; Timothy Howell; Samuel A Stewart; Erika Penz; Nikki Jordan; Anna J Morley; Natalie Zahan-Evans; Sarah Smith; Timothy J P Batchelor; Adrian Marchbank; Lesley Bishop; Alina A Ionescu; Mike Bayne; Samantha Cooper; Anthony Kerry; Peter Jenkins; Elizabeth Toy; Vallipuram Vigneswaran; James Gildersleve; Merina Ahmed; Fiona McDonald; Mick Button; Conrad Lewanski; Charles Comins; Muthukumar Dakshinamoorthy; Y C Gary Lee; Najib M Rahman; Nick A Maskell Journal: Lancet Oncol Date: 2016-06-23 Impact factor: 41.316
Authors: E Incerti; S Broggi; A Fodor; M Cuzzocrea; A M Samanes Gajate; P Mapelli; C Fiorino; I Dell'Oca; M Pasetti; M Cattaneo; R Calandrino; L Gianolli; N Di Muzio; Maria Picchio Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-06 Impact factor: 9.236